Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Debt (2010 - 2016)

Gyre Therapeutics (GYRE) reported Total Debt of $28000.0 for Q3 2016, down 95.86% year-over-year from $676000.0 in Q4 2015, and down 78.46% on a QoQ basis from $130000.0 in Q2 2016.

Gyre Therapeutics (GYRE) has 7 years of Total Debt data on file, last reported at $28000.0 in Q3 2016.

  • Quarterly Total Debt fell 95.86% year-over-year to $28000.0 in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $28000.0 (down 95.86% YoY) and the FY2015 annual result came in at $1.2 million, changed N/A from the prior year.
  • Total Debt slipped to $28000.0 in Q3 2016 per GYRE's latest filing, from $130000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $2.7 million in Q1 2012 and bottomed at $28000.0 in Q3 2016.
  • The 5-year median for Total Debt is $1.1 million (2013), against an average of $1.2 million.
  • The widest annual swing landed in 2015, when Total Debt surged 41.42%; it then tumbled 95.86% in 2016.
  • Tracing GYRE's Total Debt over 5 years: stood at $2.0 million in 2012, then sank by 42.83% to $1.1 million in 2013, then slumped by 57.92% to $478000.0 in 2014, then jumped by 141.84% to $1.2 million in 2015, then plunged by 97.58% to $28000.0 in 2016.
  • Per Business Quant, the three latest GYRE Total Debt figures stand at $28000.0 (Q3 2016), $130000.0 (Q2 2016), and $196000.0 (Q1 2016).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.96 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2016 28,000.00
Jun 30, 2016 130,000.00
Mar 31, 2016 196,000.00
Dec 31, 2015 1.16 Mn
Sep 30, 2015 676,000.00
Sep 30, 2014 478,000.00
Jun 30, 2014 699,000.00
Mar 31, 2014 918,000.00
Dec 31, 2013 1.14 Mn
Sep 30, 2013 1.35 Mn
Jun 30, 2013 1.57 Mn
Mar 31, 2013 1.78 Mn
Dec 31, 2012 1.99 Mn
Sep 30, 2012 2.20 Mn
Jun 30, 2012 2.43 Mn
Mar 31, 2012 2.67 Mn
Dec 31, 2011 3.23 Mn
Sep 30, 2011 3.79 Mn
Jun 30, 2011 4.35 Mn
Dec 31, 2010 3.06 Mn